CD133 alone cannot be used as a stem cell marker for the lung cancer cells A549 and H446, and both the CD133+ and CD133- subpopulations contain similar numbers of cancer stem cells.

CD133 positivity may be indicative of drug resistance, but it is not a prognostic marker for survival in non-small lung cell cancer patients.

non-small cell lung carcinoma patients with the dual expression of CD133 and ABCG2 have a high risk of early relapse

CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.

In the hypoxic conditions, OCT4 and SOX2, both of which are induced by HIF1alpha/HIF2alpha. promote CD133 expression in the lung cancer cells via their direct interaction with the P1 promoter.

cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer

levels of CD133, CD44, and ALDH1 had independent prognostic value to predict the recurrence of lung adenocarcinoma

CD133+ cancer stem cells are closely related with the metastasis of lung cancer, especially lymphoid metastasis, and resistance of several chemotherapeutic drugs, CD133 can have an important prognostic impact in patients with lung cancer[review]

A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.

High CD133 expression is associated with carcinogenesis of lung cancer.

CD133-positive non-small cell lung cancer patients had worse prognosis, and was associated with common clinicopathological poor prognostic factors.

we first reported that A549 CD133+ cells exhibited characteristic of high liver metastatic potential which makes it be a suitable model for further study of liver metastasis of lung adenocarcinoma

The data from the current study demonstrated novel PROM1 and CRTC2 mutations, which could promote lung cancer development

High level of CD133 expression tends to correlate with a worse prognosis and a higher rate of lymph node metastasis in non-small-cell lung cancer patients. (Meta-analysis)

Suggest that galectin-1 plays a major role on the tumorigenesis and invasiveness of CD133+ lung adenocarcinoma cells.

Results show that over-expression of both ALDH1 and CD133 were only found in non small cell carcinoma and adenocarcinoma (ADC) types of lung neoplasm but only, the low expression of ALDH1 was associated with more aggressive tumor in ADC patients.

microenvironment stimuli eliciting epithelial-to-mesenchymal transition are able to increase the dissemination potential of lung cancer cells through the generation of the CD133(+)/CXCR4(+)/EpCAM(-) subset.

CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors.

High levels of PROM1 membrane expression and combination of membrane/cytoplasm expression were associated with adverse prognosis in non-small cell lung cancer.

The study found a significant association between the SNP rs2240688A[C of CD133 and lung cancer risk.

CD133 may have different roles in survival from non-small-cell lung cancer based on ethnic groups [meta-analysis]

these results suggest that the CD133/CXCR4/epithelial-mesenchymal transition axis may be a prognostic marker and may provide novel targets for combinational therapies in the treatment of non-small cell lung cancer

Higher hazard ratios for associations between CD133 rs2240688 polymorphism and overall survival (OS) were observed in patients with adjuvant chemotherapy and radiotherapy for curative intent. The study confirmed the significant association between the SNP rs2240688 A>C of CD133 and OS of non-small cell lung cancer patients.

Association Between CD133 expression and Prognosis in Human lung Adenocarcinoma.